These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 28486415)

  • 1. The Presence of Anti-Angiotensin II Type-1 Receptor Antibodies Adversely Affect Kidney Graft Outcomes.
    Zhang J; Wang M; Liang J; Zhang M; Liu XH; Ma L
    Int J Environ Res Public Health; 2017 May; 14(5):. PubMed ID: 28486415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of anti-angiotensin II type 1 receptor antibodies on the outcomes of kidney transplantation: a systematic review and meta-analysis.
    Kang ZY; Liu C; Liu W; Li DH
    Nephrol Dial Transplant; 2022 May; 37(6):1171-1180. PubMed ID: 34865146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deleterious effect of anti-angiotensin II type 1 receptor antibodies detected pretransplant on kidney graft outcomes is both proper and synergistic with donor-specific anti-HLA antibodies.
    Malheiro J; Tafulo S; Dias L; Martins S; Fonseca I; Beirão I; Castro-Henriques A; Cabrita A
    Nephrology (Carlton); 2019 Mar; 24(3):347-356. PubMed ID: 29451342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The influence of non-HLA antibodies directed against angiotensin II type 1 receptor (AT1R) on early renal transplant outcomes.
    Banasik M; Boratyńska M; Kościelska-Kasprzak K; Kamińska D; Bartoszek D; Zabińska M; Myszka M; Zmonarski S; Protasiewicz M; Nowakowska B; Hałoń A; Chudoba P; Klinger M
    Transpl Int; 2014 Oct; 27(10):1029-38. PubMed ID: 24909812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is pre-transplant sensitization against angiotensin II type 1 receptor still a risk factor of graft and patient outcome in kidney transplantation in the anti-HLA Luminex era? A retrospective study.
    Deltombe C; Gillaizeau F; Anglicheau D; Morelon E; Trébern-Launay K; Le Borgne F; Rimbert M; Guérif P; Malard-Castagnet S; Foucher Y; Giral M
    Transpl Int; 2017 Nov; 30(11):1150-1160. PubMed ID: 28686316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pretransplant sensitization against angiotensin II type 1 receptor is a risk factor for acute rejection and graft loss.
    Giral M; Foucher Y; Dufay A; Duong Van Huyen JP; Renaudin K; Moreau A; Philippe A; Hegner B; Dechend R; Heidecke H; Brouard S; Cesbron A; Castagnet S; Devys A; Soulillou JP; Dragun D
    Am J Transplant; 2013 Oct; 13(10):2567-76. PubMed ID: 23919486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinicopathological relevance of pretransplant anti-angiotensin II type 1 receptor antibodies in renal transplantation.
    Lee J; Huh KH; Park Y; Park BG; Yang J; Jeong JC; Lee J; Park JB; Cho JH; Lee S; Ro H; Han SY; Kim MS; Kim YS; Kim SJ; Kim CD; Chung W; Park SB; Ahn C;
    Nephrol Dial Transplant; 2017 Jul; 32(7):1244-1250. PubMed ID: 26546592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-HLA antibodies: angiotensin II type 1 receptor (anti-AT1R) and endothelin-1 type A receptor (anti-ETAR) are associated with renal allograft injury and graft loss.
    Banasik M; Boratyńska M; Kościelska-Kasprzak K; Kamińska D; Zmonarski S; Mazanowska O; Krajewska M; Bartoszek D; Zabińska M; Myszka M; Kamińska M; Hałoń A; Dawiskiba T; Szyber P; Sas A; Klinger M
    Transplant Proc; 2014 Oct; 46(8):2618-21. PubMed ID: 25380879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Accelerated rejection, thrombosis, and graft failure with angiotensin II type 1 receptor antibodies.
    Pearl MH; Leuchter RK; Reed EF; Zhang Q; Ettenger RB; Tsai EW
    Pediatr Nephrol; 2015 Aug; 30(8):1371-4. PubMed ID: 25956702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigation of Serum Angiotensin II Type 1 Receptor Antibodies at the Time of Renal Allograft Rejection.
    Lee H; Kim JI; Moon IS; Chung BH; Yang CW; Kim Y; Han K; Oh EJ
    Ann Lab Med; 2015 May; 35(3):314-20. PubMed ID: 25932439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preformed Angiotensin II Type-1 Receptor Antibodies Are Associated With Rejection After Kidney Transplantation: A Single-Center, Cohort Study.
    Kim D; Gimferrer I; Warner P; Nelson K; Sibulesky L; Bakthavatsalam R; Leca N
    Transplant Proc; 2018 Dec; 50(10):3467-3472. PubMed ID: 30577222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical implications of angiotensin II type 1 receptor antibodies in antibody-mediated rejection without detectable donor-specific HLA antibodies after renal transplantation.
    Lee J; Park Y; Kim BS; Lee JG; Kim HJ; Kim YS; Huh KH
    Transplant Proc; 2015 Apr; 47(3):649-52. PubMed ID: 25891704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. C4d-negative antibody-mediated rejection with high anti-angiotensin II type I receptor antibodies in absence of donor-specific antibodies.
    Fuss A; Hope CM; Deayton S; Bennett GD; Holdsworth R; Carroll RP; Coates PT
    Nephrology (Carlton); 2015 Jul; 20(7):467-73. PubMed ID: 25726938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Impact of Pre-transplant Antibodies Against Angiotensin II Type I Receptor and Major Histocompatibility Complex Class I-Related Chain A in Kidney Transplant Patients.
    Min JW; Lee H; Choi BS; Park CW; Yang CW; Kim YS; Choi YJ; Oh EJ; Chung BH
    Ann Lab Med; 2018 Sep; 38(5):450-457. PubMed ID: 29797816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of angiotensin II type 1 receptor antibodies on post-heart transplantation outcome in Heart Mate II bridged recipients.
    Urban M; Slavcev A; Gazdic T; Ivak P; Besik J; Netuka I
    Interact Cardiovasc Thorac Surg; 2016 Mar; 22(3):292-7. PubMed ID: 26675563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful Treatment of Anti-angiotensin II Type 1 Receptor Antibody-Associated Rejection in Kidney Transplantation: A Case Report.
    Wiwattanathum P; Ingsathit A; Thammanichanond D; Worawichawong S
    Transplant Proc; 2018 Apr; 50(3):877-880. PubMed ID: 29331505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-Angiotensin II Type 1 Receptor and Anti-Endothelial Cell Antibodies: A Cross-Sectional Analysis of Pathological Findings in Allograft Biopsies.
    Philogene MC; Bagnasco S; Kraus ES; Montgomery RA; Dragun D; Leffell MS; Zachary AA; Jackson AM
    Transplantation; 2017 Mar; 101(3):608-615. PubMed ID: 27222934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histopathologic changes in anti-angiotensin II type 1 receptor antibody-positive kidney transplant recipients with acute rejection and no donor specific HLA antibodies.
    Lim MA; Palmer M; Trofe-Clark J; Bloom RD; Jackson A; Philogene MC; Kamoun M
    Hum Immunol; 2017 Apr; 78(4):350-356. PubMed ID: 28284829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The early impact of preformed angiotensin II type 1 receptor antibodies on graft function in a low immunological risk cohort of kidney transplant recipients.
    Sorohan BM; Ismail G; Berechet A; Obrișcă B; Constantinescu I; Mărunțelu I; Tacu D; Baston C; Sinescu I
    Transpl Immunol; 2021 Jun; 66():101389. PubMed ID: 33838295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-angiotensin type 1 receptor antibodies associated with antibody-mediated rejection in patients without preformed HLA-donor-specific antibody.
    In JW; Park H; Rho EY; Shin S; Park KU; Park MH; Song EY
    Transplant Proc; 2014 Dec; 46(10):3371-4. PubMed ID: 25498054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.